The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3 by Sakurai, Toshiharu et al.
Title The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3
Author(s)
Sakurai, Toshiharu; Higashitsuji, Hiroaki; Kashida, Hiroshi;
Watanabe, Tomohiro; Komeda, Yoriaki; Nagai, Tomoyuki;
Hagiwara, Satoru; Kitano, Masayuki; Nishida, Naoshi; Abe,
Takaya; Kiyonari, Hiroshi; Itho, Katsuhiko; Fujita, Jun; Kudo,
Masatoshi




Copyright: Sakurai et al. This is an open-access article
distributed under the terms of the Creative Commons
Attribution License (CC-BY), which permits unrestricted use,
distribution, and reproduction in any medium, provided the





The oncoprotein gankyrin promotes the development of colitis-
associated cancer through activation of STAT3
Toshiharu Sakurai1, Hiroaki Higashitsuji2, Hiroshi Kashida1, Tomohiro Watanabe1, 
Yoriaki Komeda1, Tomoyuki Nagai1, Satoru Hagiwara1, Masayuki Kitano1, Naoshi 
Nishida1, Takaya Abe3, Hiroshi Kiyonari3,4, Katsuhiko Itoh2, Jun Fujita2, Masatoshi 
Kudo1
1Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
2Department of Clinical Molecular Biology, Kyoto University, Kyoto, Japan
3Genetic Engineering Team, RIKEN Center for Life Science Technologies, Kobe, Japan
4Animal Resource Development Unit, RIKEN Center for Life Science Technologies, Kobe, Japan
Correspondence to: Toshiharu Sakurai, email: sakurai@med.kindai.ac.jp
Keywords: IBD, TNF, Bmi1, IL-17, treatment resistance
Received: April 20, 2016    Accepted: December 31, 2016    Published: February 01, 2017
Copyright: Sakurai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
(CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
Although long-standing colonic inflammation due to refractory inflammatory 
bowel disease (IBD) promotes the development of colitis-associated cancer (CAC), 
the molecular mechanisms accounting for the development of CAC remains largely 
unknown. In this study, we investigated the role of gankyrin in the development of 
CAC since gankyrin is overexpressed in sporadic colorectal cancers. We analyzed 
gene expression of colon tissues obtained from 344 patients with IBD and CAC and 
found that expression of gankyrin was much higher in colonic mucosa of patients 
with refractory IBD than in those with IBD in remission. Expression of gankyrin 
was upregulated in inflammatory cells as well as tumor cells in colonic mucosa of 
patients with CAC. Over-expressing studies utilizing tagged ganlyrin-cDNA identified 
physical interaction between ganlyrin and Src homology 2-containing protein tyrosine 
phosphatase-1 (SHP-1). Importantly, the interaction between ganlyrin and SHP-
1 leads to inhibition of STAT3 activation and to enhancement of TNF-α and IL-17 
in inflammatory cells. To further address the role of gankyrin in the development 
of CAC, we created mice with intestinal epithelial cell-specific gankyrin ablation 
(Vil-Cre;Gankyrinf/f) and deletion of gankyrin in myeloid and epithelial cells (Mx1-
Cre;Gankyrinf/f). Gankyrin deficiency in myeloid cells, but not in epithelial cells, 
reduced the activity of mitogen activated protein kinase and the expression of stem 
cell markers, leading to attenuated tumorigenic potential. These findings provide 
important insights into the pathogenesis of CAC and suggest that gankyrin is a 
promising target for developing therapeutic and preventive strategies against CAC.
INTRODUCTION
Colorectal cancer is one of the most leading causes 
of cancer-related death worldwide [1, 2]. Inflammatory 
bowel diseases (IBD); ulcerative colitis (UC) and 
Crohn’s disease (CD) are thought to result from aberrant 
activation of the intestinal immune system [3] and are 
major risk factors for colorectal cancer, so-called colitis-
associated cancer (CAC) [4]. Indeed, patients with IBD 
with refractory and longstanding colitis bear higher risk of 
colorectal cancer than individuals in the general population 
[5]. However, the exact molecular mechanisms underlying 
CAC remain unclear. In our previous reports, we found 
that stress response proteins induced in longstanding 
inflamed mucosa promote the development of CAC [6, 7]. 
In addition, we found that heat shock protein A4 (HSPA4) 
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expression could predict poor therapeutic response to 
steroid in IBD patients. These data suggest that persistent 
inflammation can result in treatment resistance and 
refractory clinical course, then thereby increase the risk 
of CAC in IBD due to enhanced stress protein responses.
Gankyrin (also known as PSMD10, p28 and Nas6p) 
is an oncoprotein overexpressed in many malignancies 
including hepatocellular carcinoma, cholangiocellular 
carcinoma, colorectal cancer and lung cancer [8–12]. 
Given the fact that gankyrin enhances proliferation and 
death evasion in cancer cell lines [13–15], uncontrolled 
cell-autonomous events underlie the pathogenesis of cancer 
development through over-expression of ganlyrin. It should 
be noted, however, that the tumor microenvironment 
makes a major contribution and influences the physiology 
of malignant cells [16] in addition to cell-autonomous 
events such as proliferation and death evasion. At present, 
little has been understood regarding the involvement of 
gankyrin in inflammation-associated cancer.
Here we examined whether gankyrin plays a role 
in inflammation-associated tumorigenesis in the colon 
using a murine CAC model in which two kinds of tissue-
specific gankyrin-deficient mice, intestinal epithelial cell-
specific gankyrin ablation (Vil-Cre;Gankyrinf/f) mice and 
deletion of gankyrin in both myeloid and epithelial cells 
(Mx1-Cre;Gankyrinf/f) mice, were employed. We found 
that expression of gankyrin in myeloid cells rather than 
in epithelial cells is required for efficient tumorigenesis. 
Mechanistically, binding of gankyrin to SH2-containing 
protein tyrosine phosphatase-1 (SHP-1, also known as 
PTPN6) enhances the pro-inflammatory cytokine responses 
in myeloid cells through activation of signal transducer 
and activator of transcription-3 (STAT3) [17, 18] and 
then promotes colorectal tumorigenesis. Consistent with 
these results, refractory inflammation is associated with 
increased gankyrin expression in the colonic mucosa of 
patients with refractory IBD, which would increase the risk 
for CAC. Taken together, this study provides the evidence 
that gankyrin expression underlie the pathogenesis of 
inflammation-associated tumorigenesis.
RESULTS
Gankyrin expression is increased in the colonic 
mucosa of patients with refractory IBD
In our previous study, we showed that longstanding 
intestinal inflammation increases the expression of stress 
response proteins including HSPA4 in the colonic mucosa 
of IBD patients. Interestingly, such increased expression 
of HSPA4 was accompanied by that of gankyrin, 
which suggests possible involvement of ganlyrin in the 
development of long-standing colonic inflammation [7]. 
Based on these data, in this study we addressed whether 
an association exists between gankyrin expression and the 
clinical status of IBD patients. For this purpose, we obtained 
colonic biopsy specimens from patients with refractory 
IBD, non-refractory IBD, and IBD in remission. The 
disease characteristics were shown in Supplementary Table 
1. Gankyrin expression levels were increased in patients 
with refractory IBD as compared with those in controls or 
IBD patients in remission (Figure 1A, 1B). By contrast, no 
significant difference was seen in gankyrin expression levels 
between non-refractory IBD patients and those in remission 
(Figure 1B), Serum albumin levels were significantly lower 
and Mayo endoscopic scores were significantly higher 
in non-refractory and refractory IBD patients than those 
in IBD patients in remission (Table S1). Thus, gankyrin 
expression was associated with the disease activity of IBD.
We then performed immunohistochemical studies 
to identify the cells expressing gankyrin in the human 
colon tissues. Gankyrin expression was enhanced in 
inflammatory cells as well as epithelial cells in chronically 
inflamed mucosa (Figure 1A). In addition, gankyrin 
expression was up-regulated in all human CAC cases 
(total n=10) and was detected in inflammatory cells as 
well as epithelial cells and tumor cells (Figure 1A). Taken 
together, these data suggest that expression of gankyrin 
is up-regulated in inflammatory cells, epithelial cells, 
and tumor cells in the colonic mucosa of patients with 
refractory IBD and CAC.
Gankyrin expression is correlated with 
expression of pro-inflammatory cytokines and 
stem cell markers
It is generally accepted that colonic mucosa of 
patients with IBD is characterized by pro-inflammatory 
cytokine responses. Th17 pathways induced by myeloid 
cell production of IL-6 and IL-23 have been implicated in 
the immuno-pathogenesis of IBD [19]. Therefore, we next 
assessed the relationship between pro-inflammatory Th17 
responses and gankyrin expression in colonic mucosa of 
IBD. To this end, expression levels of IL-6, IL-23p19, and 
IL-17A were determined. Gankyrin expression correlated 
weakly but significantly with IL-6 expression with a linear 
coefficient of 0.26 in the colonic mucosa of UC patients 
but not of CD patients (Supplementary Figure 1A-1B). A 
significant correlation was seen between Gankyrin and 
IL-17A or IL-23p19 mRNA expression in UC patients 
(Figure 1C–1D). Thus, it is likely that gankyrin could act 
in concert with pro-inflammatory Th17 responses to cause 
chronic colonic inflammation.
Having obtained positive correlation between pro-
inflammatory cytokine responses and ganlyrin, we next 
turned our attention to a linkage between expression 
levels of gankyrin and stem cell markers. Leucine-rich 
repeat-containing G-protein-coupled receptor 5 (Lgr5) is a 
prototypical marker of the self-renewing multipotent adult 
stem cell populations residing in intestinal crypts that mediate 
regeneration of the intestinal epithelium [20]. Lgr5 expressed 
in intestinal stem cells has also been shown to self-renew and 
continuously replenish tumor progeny [21]. B cell-specific 
Moloney murine leukemia virus insertion site 1 (Bmi1) 
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is frequently overexpressed in human sporadic colorectal 
cancer and the degree of upregulation correlates with disease 
progression and is predictive of poor patient survival [22]. 
In mice, Bmi1 is required for intestinal tumorigenesis [23]. 
In UC patients, a significant correlation was found between 
Lgr5 and Bmi1 expression (Supplementary Figure 1C). 
Interestingly, gankyrin expression significantly correlated 
with Bmi1 and Lgr5 expression with linear coefficients of 
0.52 and 0.27, respectively in UC and correlated with Bmi1 
expression in CD (Figure 1E and Supplementary Figure 1D–
1E). Although gankyrin expression was shown to correlate 
with stemness factor Nanog expression in human sporadic 
colorectal cancer in previous study [10], no significant 
correlation was found between the expression of these genes 
in IBD patients (Supplementary Figure 1F). This positive 
correlation between gankyrin and Lgr5 or Bmi1 suggests 
that gankyrin might be related with cancer stem cell behavior 
in IBD patients.
Gankyrin deficiency attenuates tumorigenesis in 
the murine CAC model
Chronic inflammation increases intestinal cancer 
risk in IBD [24]. To investigate the precise pathogenic 
mechanisms underlying IBD-associated colorectal 
carcinogenesis, we used the AOM plus DSS mouse model 
to study the role of gankyrin in CAC. Since gankyrin 
expression was up-regulated in a wide variety of cells 
including immune cells, epithelial cells, and tumor cells 
in human IBD and CAC samples, we initially tried to 
determine the role of gankyrin in the AOM-DSS mouse 
model. To this end, we created Gankyrinf/f mice (Figure 
2A) and then crossed with Mx1-Cre mice to generate 
Mx1-Cre-driven gankyrin deficient mice (termed Mx1-
Cre;Gankyrinf/f mice).
In the AOM/DSS protocol, a significant decrease 
was noted in the number and maximum size of tumors in 
Figure 1: Gankyrin expression is increased in the colonic mucosa of patients with refractory IBD. A. Representative 
images of immunohistochemical findings in human colonic mucosa of patients without IBD and those with refractory UC and human 
colitis-associated cancer (CAC) using anti-gankyrin antibody. Scale bar, 100 μm. B. Expression of gankyrin mRNA in normal colonic 
mucosa (Control, n = 54), colonic mucosa of IBD patients in remission (In remission, n = 47), those with non-refractory active IBD (Non-
refractory, n = 115), and those with refractory IBD (Refractory, n = 128), as determined by quantitative real-time qPCR. P values were 
calculated by post-hoc Tukey-Kramer HSD multiple comparison. C-E. Scatter plot of relative mRNA levels of gankyrin and the respective 
genes in human colonic mucosa.
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Figure 2: Gankyrin deficiency in myeloid cells attenuates tumorigenesis in the murine CAC model.A. Construction of 
the wild-type allele, targeting vector, floxed allele and deleted allele of the mouse Gankyrin gene. The targeting vector contained the neor 
cassette for selection, and loxP fragments were located on both sides of exon 1 to delete this exon. B. Typical examples of macroscopic 
tumorigenesis in the CAC model. Gankyrinf/f (GKf/f) mice and Mx1-Cre;Gankyrinf/f (Mx1-Cre;GKf/f) mice were challenged with AOM and 
DSS, and colons were cut longitudinally. C, D. Tumor number (C) and maximum size (D, GKf/f mice, n = 10; Mx1-Cre;GKf/f mice, n = 10). 
E. Mx1-Cre;GKf/f mice and GKf/f mice were challenged with AOM and DSS. Representative images of immunohistochemical detection 
of gankyrin are shown. Scale bar, 100 μm. F. Colon length after treatment with AOM and DSS. GKf/f mice, n = 6; Mx1-Cre;GKf/f mice, n 
= 6. Data are means ± SEM. *P < 0.05 compared with GKf/f mice. G. Inflammatory cell infiltration into colonic tissues of GKf/f mice and 
Mx1-Cre;GKf/f mice 7 days after the initiation of DSS administration. GKf/f mice, n = 5; Mx1-Cre;GKf/f mice, n = 5. Data are means ± 
SEM. *P < 0.05 compared with GKf/f mice. H. Typical examples of macroscopic tumorigenesis in the CAC model. GKf/f mice and Villin-
Cre;Gankyrinf/f (Vil-Cre;GKf/f) mice were challenged with AOM and DSS, and colons were cut longitudinally.
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the Mx1-Cre;Gankyrinf/f mice compared with Gankyrinf/f 
controls (Figure 2B–2D). These tumors were located in 
the middle to distal colon, which is similar to human CAC. 
In Gankyrinf/f mice, gankyrin expression was detected 
in both epithelial and in lamina propria immune cells 
of non-tumor colonic tissue by immuno-histochemical 
analysis. In the colonic tumor lesions, both tumor cells 
and surrounding stromal cells expressed gankyrin protein 
(Figure 2E). Gankyrin expression was much lower both in 
myeloid and epithelial cells of non-tumor colonic tissue 
of Mx1-Cre;Gankyrinf/f mice as compared with Gankyrinf/f 
controls. Gankyrin was absent in most of tumors of Mx1-
Cre;Gankyrinf/f mice; however, a few tumors expressed 
gankyrin protein (Figure 2E and Supplementary Figure 
2A). Thus, these data utilizing the AOM-DSS model 
suggest that gankyrin expression in myeloid cells and/or 
epithelial cells is associated with the development of CAC.
We next assessed the effects of gankyrin deletion on 
the chronic inflammatory responses in this model. Colon 
length was measured as one parameter to evaluate the 
severity of inflammation and was found to be significantly 
longer in Mx1-Cre;Gankyrinf/f mice than in Gankyrinf/f 
mice (Figure 2F). Pathological analysis of non-tumor 
portions showed a marked infiltration of immune cells in 
Mx1-Cre;Gankyrinf/f mice as compared with Gankyrinf/f 
mice (Supplementary Figure 2B). No differences in body 
weight could be detected between Mx1-Cre;Gankyrinf/f 
mice and Gankyrinf/f mice during the CAC regimen 
(Supplementary Figure 2C).
To assess the effect of gankyrin on acute 
inflammation, experimental colitis was induced by 
treating mice with 2.5% DSS for 7 days. The degree of 
inflammatory cell infiltration into the colon was lower in 
Mx1-Cre;Gankyrinf/f mice than in Gankyrinf/f mice (Figure 
2G and Supplementary Figure 3A). Apoptosis detected by 
TUNEL staining was observed primarily in the colonic 
crypts and was not affected by gankyrin disruption 
(Supplementary Figure 3B). In addition, no significant 
difference in body weight was found during the seven-
day colitis regimen (Supplementary Figure 3C). These 
data altogether suggest that loss of gankyrin expression 
in hematopoietic and non-hematopoietic cells leads to the 
prevention of CAC development through the attenuation 
of inflammatory responses.
Gankyrin in myeloid cells is critical for efficient 
tumorigenesis in the murine CAC model
To functionally characterize the contribution of 
different cell populations to colitis development, we 
created bone marrow-chimeric mice using a combination 
of gamma irradiation and bone marrow transplantation 
(BMT). Non-transplanted irradiated mice survived less 
than 2 weeks after irradiation, indicating successful 
deletion of BM cells by gamma irradiation. Irradiated 
animals that received BMT were allowed to recover 
for 2 months prior to placing them on the DSS-induced 
colitis protocol. Inflammatory cell infiltration scores of 
irradiated gankyrin-intact mice harbouring gankyrin-
deficient BM cells was lower than those harbouring 
gankyrin-intact BM cells (Supplementary Figure 3D), 
which indicates that gankyrin expressed in hematopoietic 
cells is involved in the attenuated inflammation observed 
in Mx1-Cre;gankyrinf/f mice. To address the therapeutic 
ability of gankyrin inhibition, we injected poly(I:C) 
into Mx1-Cre;Gankyrinf/f mice and deleted gankyrin 
after the initiation of DSS treatment. Inflammation was 
slightly attenuated by gankyrin deletion after the DSS 
treatment (Supplementary Figure 3E). Consistent with 
the data shown above, flow-cytometric analysis revealed 
that CD3+ T cells, CD11b+ myeloid cells, and CD20+ B 
cells were positive for intracellular gankyrin expression 
(Supplementary Figure 4A).
In Mx1-Cre;Gankyrinf/f mice, gankyrin was 
deleted in the liver as well. To confirm the role of 
gankyrin expression in the colon, we created Albumin-
Cre;gankyrinf/f mice where gankyrin is deficient only in 
the liver (Sakurai et al., unpublished data) and compared 
Albumin-Cre;gankyrinf/f mice and gankyrinf/f mice in 
colitis model. No difference in DSS-induced colonic 
inflammation was seen between Albumin-Cre;gankyrinf/f 
mice and gankyrinf/f mice (Supplementary Figure 4B), 
suggesting that gankyrin deficiency in the colon, but 
not the liver, affects the phenotype observed in DSS-
challenged Mx1-Cre;gankyrinf/f mice.
Mice lacking gankyrin only in their intestinal 
epithelial cells (Vil-Cre;Gankyrinf/f mice) and their 
littermate controls (Gankyrinf/f mice) were challenged 
with AOM and DSS to confirm a role of myeloid cells 
expressing gankyrin. Deletion of gankyrin in enterocytes 
did not show gross abnormalities. No significant 
differences were seen in tumor numbers or maximum 
sizes between Vil-Cre;Gankyrinf/f mice and control 
Gankyrinf/f mice in the murine CAC model (Figure 2H 
and Supplementary Figure 5A-5B). Collectively, these 
data suggest that gankyrin promotes tumorigenesis mainly 
through its actions in myeloid cells rather than epithelial 
cells.
Gankyrin interacts with SHP-1 in myeloid cells
To further characterize the tumorigenic activity of 
gankyrin, we performed a yeast two-hybrid assay using 
the full length of gankyrin as bait, and found that gankyrin 
bound to SHP-1 in the yeast. To confirm that gankyrin 
interacts with SHP-1 in mammalian cells, U-2 OS cells 
were co-transfected with plasmids expressing HA-tagged 
human gankyrin and FLAG-tagged SHP-1. When cell 
lysates were immunoprecipitated with an anti-FLAG 
antibody, HA-gankyrin was detected in the precipitates. 
Reciprocally, SHP-1 was detected in the anti-HA 
immunoprecipitates from cells co-transfected with plasmid 
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expressing HA-gankyrin and FLAG-SHP-1 (Figure 3A). 
Thus, a physical interaction between gankyrin and SHP-1 
was confirmed in over-expression studies.
We next addressed a physioligical role played by 
the interaction between ganlyrin and SHP-1 in AOM-
DSS model. In Gankyrinf/f mice challenged with AOM 
and DSS, SHP-1 was expressed mainly in inflammatory 
or stromal cells as well as tumor cells (Figure 3B). Double 
immunofluorescence staining showed that both gankyrin 
and SHP-1 proteins were co-localized in the cytoplasm 
and the nucleus of these cells (Figure 3C). Finally, we 
employed, the Duolink Assay for the visulalization of 
interaction between gankyrin and SHP-1. The molecular 
interaction between ganlyrin and SHP-1 visualized as red 
punctate dots were mainly seen in non-epithelial cells, 
but not epitherlila cells (Figure 3D). These data suggest 
that the molecular interaction between gankyrin and SHP-
Figure 3: Gankyrin interacts with SHP1 in vitro and in vivo. A. Coimmunoprecipitation (IP) of exogenous proteins. U-2 OS cells 
were cotransfected with plasmids expressing HA-gankyrin and FLAG-SHP-1. Immunoprecipitates prepared by IP with indicated antibodies 
were analyzed by western blotting (WB). B. Representative images of immunohistochemical detection of SHP-1 in colonic tissues and 
tumors of Gankyrinf/f mice treated with AOM and DSS. Scale bar, 100 μm. C. Representative images of immunohistochemical detection 
of SHP-1 and gankyrin in colonic tissues from tumor-harboring Gankyrinf/f mice. D. Interaction of gankyrin with SHP-1 was assessed by 
Duolink Assay in AOM/DSS-treated Gankyrinf/f mice. E. Lysates from THP-1 cells transfected with gankyrin RNAi (GK siRNA) or control 
RNAi (Control) were analyzed by WB using indicated antibodies.
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1 is operating in non-epithelila cells i.e., hematopoietic 
myleloid cells, in AOM-DSS model.
Interaction of gankyrin with SHP-1 results in 
activation of STAT3 and MAP kinase
SHP-1 is well-known inhibitor of activation-
promoting signaling cascades in hematopoietic cells [25] 
and negatively regulates signaling by dephosphorylating 
STAT3, ERK, JNK and p38 [17, 18, 26, 27]. Having 
obtained the induction of gankyrin-SHP1 interaction in 
hematopoietic cells, we next assessed the effects of such 
interaction on these signaling pathways in myeloid cells. 
To this end, we utilized THP-1 cells, an immortalized line 
of human monocyte. Knockdown of gankyrin expression 
by ganlyrin-specific siRNA reduced STAT3 and p38 
phosphorylation in immuno-blotting analysis (Figure 3E). 
Thus, gankyrin promotes activation of STAT3 and mitogen- 
activated protein kinase (MAP kinase). In colon tumor 
cells, knockdown of gankyrin reduced cell viability while 
knockdown of SHP-1 increased it (Supplementary Figure 
6A). In contrast, overexpression of gankyrin did not affect 
SHP-1 phosphatase activity probably because of much 
endogenous gankyrin protein (Supplementary Figure 6B).
Then, we assessed the effects of gankyrin on the 
signaling pathways in vivo. Consistent with the data 
obtained from human THP-1 cells, Mx1-Cre;Gankyrinf/f 
mice exhibited reduced activation of STAT3, ERK 
and p38 compared with Gankyrinf/f controls (Figure 
4A and 4B). Immunohistochemical analysis revealed 
Figure 4: Gankyrin activates STAT3 in non-tumor tissues and ERK in tumors. A. Mx1-Cre;Gankyrinf/f (Mx1-Cre;GKf/f) mice 
and Gankyrinf/f (GKf/f) mice were challenged with AOM and DSS. Homogenates of non-treated colons (Control), non-tumor colon tissues 
(Non-tumor) and tumors (Tumor) were gel-separated and immunoblotted with the indicated antibodies. B. Relative kinase activities in 
non-tumor colon tissues (Non-tumor) and tumors (Tumor) isolated from Mx1-Cre;Gankyrinf/f (Mx1-Cre;GKf/f) mice and Gankyrinf/f (GKf/f) 
mice challenged with AOM and DSS were assessed by densitometry. Kinase activity in untreated Gankyrinf/f mice was given an arbitrary 
value of 1. Data are means ± SEM. C, D. Representative images of immunohistochemical detection of phosphorylated STAT3 (C) and 
phosphorylated ERK (D) in non-tumor colon tissues (Non-tumor) and tumors (Tumor). Scale bar, 100 μm.
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that the activities of STAT3 and ERK were reduced in 
inflammatory cells but not in intestinal epithelial cells 
in gankyrin-deficient colons (Figure 4C and 4D). In 
contrast, tumors isolated from Mx1-Cre;Gankyrinf/f mice 
showed similar level of phosphorylated STAT3 and 
lower level of phosphorylated ERK compared with those 
from control Gankyrinf/f mice (Figure 4A, 4B and 4D). 
Colorectal tissues isolated from Vil-Cre;Gankyrinf/f mice 
exhibited similar level of phosphorylated STAT3 and 
ERK compared with control counterparts (Supplementary 
Figure 5C). Thus, these data suggest that gankyrin 
deletion leads to reduced activation of STAT3 and 
MAP kinase in inflammatory myeloid cells rather than 
epithelial cells in AOM-DSS model.
We assessed the effect of gankyrin on these signaling 
pathways in DSS-induced colitis model. Examination of 
the colonic lysates from DSS-treated Villin-Cre;Gankyrinf/f 
mice and Gankyrinf/f controls showed that gankyrin 
deletion resulted in reduced STAT3 phosphorylation but 
a minor change in ERK phosphorylation (Supplementary 
Figure 7A), whcih suggests a possibel involvement of 
gankyrin-SHP1 interaction in the activation of STAT3 and 
MAP kinase in acute epithelial cell injury.
Loss of gankyrin in myeloid cells results in 
reduced expression of cytokines and stem cell 
markers
The associated immune response was investigated 
by analyzing colonic cytokine levels. Colonic tissue from 
Mx1-Cre;Gankyrinf/f mice showed lower levels of pro-
inflammatory cytokine TNF-α than that of control mice 
(Figure 5A) as assessed by qPCR analysis, which would 
be due to reduced activities of STAT3 and MAP kinase in 
inflammatory cells. To further characterize the effects of 
gankyrin on cytokine production, we sought to confirm 
these findings in vitro. In LP cells isolated from DSS-
treated colons of Mx1-Cre;Gankyrinf/f mice, expression of 
TNF-α and IL-17 was decreased compared with those of 
control mice (Figure 5B), which is consistent with the data 
in humans (Figure 1C).
It is genellay accepted that pro-inflammatory 
cytokine responses affect the expression of stem cell 
markers and proliferation of stem cells [28]. Therefore, 
we addressed the effects of gankyrin deletion on the 
expression of cancer stem cell markers. Colonic tissue 
from Mx1-Cre;Gankyrinf/f mice showed lower levels 
of Bmi1 than that of Gankyrinf/f mice when they were 
treated with AOM and DSS (Figure 5A). In contrast, 
no difference was found in the level of Bmi1 between 
similarly treated Vil-Cre;Gankyrinf/f mice and Gankyrinf/f 
mice (Supplementary Figure 5D).
In Mx1-Cre;Gankyrinf/f mice, STAT3 activity was 
decreased in inflammatory cells whilst ERK activity was 
decreased in tumor cells as well as inflammatory cells. 
Provirus integration site for Moloney murine leukemia 
virus (Pim1) is linked to the development and progression 
of several cancers including colorectal cancer [29]. Sox9 
[sex-determining region Y (SRY)-box 9 protein], an 
intestinal stem cell marker, plays critical roles during 
embryogenesis and its activity is required for development, 
differentiation, and lineage commitment in various tissues 
including the intestinal epithelium [30]. Since expression 
of Pim1 and Sox9 requires activation of STAT3 and 
ERK, respectively, we assessed the expression of Pim1 
and Sox9 in AOM-DSS model utilizing conditional 
gankyrin–deficient mice. Expression of Pim1 was down-
regulated in gankyrin-deficient colons compared to 
control counterparts (Figure 5A). Furthermore, LP cells 
derived from Mx1-Cre;Gankyrinf/f mice, but not from Vil-
Cre;Gankyrinf/f mice, exhibited marked down-regulation 
of Pim1 mRNA relative to those isolated from Gankyrinf/f 
mice (Figure 5B and Supplementary Figure 7B). Sox9 
mRNA expression was significantly reduced in gankyrin-
deficient tumors (Figure 5C). Another stem cell marker 
achaete-scute complex homolog 2 (Ascl2) is suggested to 
regulate the development of colorectal cancer via CDX2 
[31]. Gankyrin ablation also decreased the expression of 
Ascl2 (Figure 5C). In addition, expression of cMyc, a 
prototypical oncogene, was reduced in gankyrin-deficient 
mice as compared with gankyrin-intact mice (Figure 5C). 
Taken together, these data support the idea that gankyrin 
deletion leads to a reduction of pro-inflammatory cytokine 
responses and expression of cancer stem cell markers 
through inhibition of STAT3 and/or ERK activation.
In THP-1 cells, an immortalized line of human 
monocyte, knockdown of gankyrin reduced the expression 
of TNF-α and Pim1 (Figure 5D) through the inhibition of 
p38 and STAT3 activation (Figure 3E). In contrast, the 
effect of gankyrin on ERK activation was marginal in 
THP-1 cells (Figure 3E). These data indicate that gankyrin 
activates STAT3 in a cell-autonomous manner, leading to 
increased expression of their target genes such as TNF-α, 
which might at least partially contribute to the enhanced 
MAP kinase ERK activation in a non-cell-autonomous 
manner.
DISCUSSION
In the context of chronic inflammation, cytokines 
secreted by immune cells contribute to creating the cancer-
microenvironment in which activation and proliferation of 
cancer stem cells are promoted [28]. Indeed, a recent study 
has suggested that colorectal cancer tissue-derived Foxp3+ 
IL-17+ cells have the capacity to induce cancer-initiating 
cells in vitro [32]. Thus, it is generally accepted that 
cytokine-mediated inflammatory signaling pathways are 
important for dedifferentiation and generation of tumor-
initiating cells [33]. However, the precise mechanisms 
accounting for the activation of cancer-initiating cells 
in response to pro-inflammatory cytokines have been 
poorly defined. In this study, we provide the evidence 
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that gankyrin expressed in myeloid cells promote the 
expansion of cancer-initiating cells through the induction 
of cancer stem cell markers such as Pim1 and Sox9. As 
for the mechanisms of ganlyrin-induced inflammatory 
responses by myeloid cells, we show that molecular 
interaction between gankyrin and SHP1 leads to secretion 
of pro-inflammatory cytokine. Thus, we have elucidated 
a part of molecular mechanisms for the development of 
inflammation-associated colon carcinogenesis by focusing 
on the function of myeloid cell expression of gankyrin.
Previous studies report that upregulation of 
gankyrin was detected in many tumor cell lines and 
primary tumors. Such enhanced expression of gankyrin 
has been considered to promote the prolifearion of cancer 
cells by inhibiting apoptosis and cell cycle in cell lines 
[8–14]. However, until now it was not clear whether 
gankyrin is instrumental for tumor development in vivo. 
In this study, we tried to determine the role of gankyrin 
in the interface between tumor cells and immune cells. 
We found that gankryin upregulates IL-17 expression in 
Figure 5: Loss of gankyrin in myeloid cells results in reduced expression of cytokines and stem cell markers. A. RNA 
was extracted from non-tumor colon of tumor-harboring Mx1-Cre;Gankyrinf/f (Mx1-Cre;GKf/f) mice and Gankyrinf/f (GKf/f) mice. Relative 
amounts of mRNA were determined by real-time qPCR and normalized to the amount of actin mRNA. The amount of each mRNA in the 
untreated colon was given an arbitrary value of 1.0. Data are means ± SEM (n = 5). B. Effect of gankyrin on gene expression in colonic 
lamina propria (LP) cells. LP cells were isolated from DSS-treated Mx1-Cre;Gankyrinf/f (Mx1-Cre;GKf/f) mice and Gankyrinf/f (GKf/f) mice 
and cytokine mRNA expression was analyzed by real-time qPCR. The mRNA expression levels in LP cells from non-treated WT mice were 
set as 1. C. RNA was extracted from tumor tissues of Mx1-Cre;Gankyrinf/f (Mx1-Cre;GKf/f) mice and Gankyrinf/f (GKf/f) mice. Relative 
amounts of mRNA of ERK target genes cMyc, and stem cell markers Sox9, Bmi1, Lgr5 and Ascl2 were determined by real-time qPCR 
and normalized to the amount of actin mRNA. The amount of each mRNA in the untreated colon was given an arbitrary value of 1.0. Data 
are means ± SEM (n = 5). D. Relative amounts of mRNA of TNF-α and Pim1 from THP-1 cells transfected with gankyrin RNAi or control 
RNAi were determined by real-time qPCR and normalized to the amount of actin mRNA. The amount of each mRNA in the untreated colon 
was given an arbitrary value of 1.0. Data are means ± SEM (n = 3).
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lamina propria cells in murine AOM-DSS CAC model. 
In addition, we showed that expression of gankyrin was 
positively correlated with that of IL-17A. Recent study by 
Wang K et al. show that IL-17A exerts its pro-tumorigenic 
activity through its type A receptor (IL-17RA), which 
signals directly within transformed colonic epithelial cells 
to promote early tumor development by activating MAP 
kinase, especially ERK signaling [34]. Consistent with 
this report, a significant reduction of IL-17 production 
was seen in the colonic mucosa of gankyrin-deficient mice 
upon AOM-DSS treatment, which effect was accompanied 
by a reduction in MAP kinase activation and in expression 
of cancer stem cell markers. Thus, IL-17 signaling might 
mediate the gankyrin-mediated cross-talk between 
immune cells and tumor cells.
Another pro-inflammatory cytokine associated with 
the development of CAC through activation of gankyrin 
is TNF-α. Expression of TNF-α was positively correlated 
with that of gankyrin in human IBD samples. In addition, 
TNF-α expression was significantly lower in gankyrin-
deficient mice treated with AOM-DSS than in gankyrin-
intact mice. Furthermore, ganlyrin-knowdown leads to a 
diminished TNF-α production by human monocytic cells 
through inhibition of STAT3 and MAP kinase activation, 
which suggests involvement of gankyrn-mediated 
signaling pathways for optimal production of TNF-α. 
Given the fact that TNF-α produced by myeloid cells is a 
critical player for the longstanding chronic inflammation 
and CAC [35], the results of the present study provide 
another important linkage between gankyrin-mediated 
TNF-α production and colon carcinogenesis.
In this study, we created two kinds of conditional 
gankyrin-deficient mice; Mx1-Cre;Gankyrinf/f mice 
and Vil-Cre;Gankyrinf/f mice. Deletion of gankyrin 
was confirmed in hemapoietic and non-hematopoietic 
cells in Mx1-Cre;Gankyrinf/f mice whereas deletion 
was confirmed in epithelial cells in Vil-Cre;Gankyrinf/f 
mice. The development of CAC induced by AOM-DSS 
treatment was significantly attenuated in the colon of 
Mx1-Cre;Gankyrinf/f mice as compared with control 
Gankyrinf/f mice. In contrast, the development of CAC 
induced by AOM-DSS treatment was comparable between 
Vil-Cre;Gankyrinf/f mice and control Gankyrinf/f mice. 
Similarly, Mx1-Cre;Gankyrinf/f mice exhibited attenuated 
inflammatory scores upon acute DSS colitis model. In 
line with this, the development of acute DSS colitis was 
attenuated in irradiated-gankyrin-intact mice transplanted 
gankyrin-deficient BM cells as compared with thoses 
transplanted with gankyrin-intact BM cells. These studies 
utilizing two kinds of conditional gankyrin-deficient mice 
together with BMT experiments strongly suggest a pivotal 
role played by hematopoietic cells expressing gankyrin in 
the development of chronic colitis and colitis-associated 
cancer. Compatible to this idea, gankyrin expression 
was detected in immune cells of the colon tissue of 
human CAC and refractory IBD samples. Moreover, pro-
inflammatory cytokine responses such as TNF-α and IL-17 
were significantly reduced in the colon tissues of AOM-
DSS-treated Mx1-Cre;Gankyrinf/f mice, which effects 
were again accompanied by a reduction in expression 
of cancer stem cell markers and in activation of STAT3 
and MAP kinase activation. Thus, it is very likely that 
myeloid cells expressing gankyrin play an indispensable 
role in the development of chronic colitis and CAC 
through the enhancement of pro-inflammatory cytokine 
responses, activation of STAT3 and MAP kinases, and 
finally expression of cancer stem cell markers. Therefore, 
present findings show for the first time that as a tumor 
promoter gankyrin can enhance tumor development 
through the interaction between tumor cells and immune 
cells. It should be noted, however, that we cannot exclude 
a role played by gankyrin-expressing epithelial cells. 
Gankyrin in epithelial cells would at least partly contribute 
to tumorigenesis in another type of cancer such as sporadic 
colorectal cancer rather than CAC.
One question arising from the present study is 
whether gankyrn expression is up-regulated not only in 
IBD but also in non-chronic inflammatory diseases such 
as infectious or ischemic colitis in human samples. In this 
regards, we do not have enough specimens of non-chronic 
inflammatory diseases and thus cannot provide the data of 
gankyrin expression in non-chronic inflammatory diseases. 
However, our preliminary assay utilizing biopsy samples 
from Amoebatic dyscentery revealed that the gankyrin 
expression was found to be lower than that in IBD patients.
The most feared long-term complication of IBD 
is CAC as patients with IBD have an increased risk of 
colorectal cancer [5]. Most cases of CAC arise from 
dysplasia, and surveillance colonoscopy is therefore 
recommended to detect dysplasia. Recently, it was 
suggested that intensified surveillance and endoscopic 
resection of dysplasia might prevent CAC [36], which is 
a new strategy to improve quality of life for patients. If 
we can reliably predict an individual’s risk of dysplasia 
and CAC, surveillance strategies could be appropriately 
personalized and surveillance programs would become 
more cost-effective. As shown in the present study, high 
level of gankyrin expression in the colonic mucosae 
reflects the presence of refractory inflammation. This 
suggests that gankyrin can be used as a potential marker 
for predicting the risk of CAC development. Indeed, 
expression of gankyrin was increased in human CAC 
tissues as well. Furthermore, gankyrin expression was 
reported to be upregulated during the development of 
another type of cancer [15, 37]. Analyzing the gankyrin 
level may be utilized to predict the risk of cancer and 
prognosis of IBD patients.
In this study, we propose that gankyrin expressed 
in myeloid cells promotes CAC through induction of 
pro-inflammatory cytokine responses and expression of 
cancer stem cell markers. The chain of evidence supporting 
this conclusion consisted first of the fact that gankyrin 
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expression is correlated with the expression of immune 
cell-derived pro-inflammatory IL-17-related cytokines and 
with that of stem cell marker (Lgr5) in the colonic mucosa 
of IBD patients. Moreover, immuno-histochemical analysis 
revealed the expression of gankyrin in immune cells 
migrated into the colonic mucosa of patients with refractory 
IBD and CAC. These results obtained from human samples 
were further corroborated in experimental studies utilizing 
Mx1-Cre;Gankyrinf/f mice and Vil-Cre;Gankyrinf/f mice. 
As mentioned above, Mx1-Cre;Gankyrinf/f mice lacking 
gankyrin in hematopoietic cells and epithelial cells, but 
not Vil-Cre;Gankyrinf/f mice lacking gankyrin in epithelial 
cells alone, were resistant to the development of acute 
colitis and inflammation-associated colon tumorigenesis. 
Importantly, such resistance to inflammation-associated 
colon tumorigenesis in Mx1-Cre;Gankyrinf/f mice was 
associated with a significant reduction of pro-inflammatory 
responses (IL-17 and TNF-α) and expression of cancer stem 
cell markers (Bmi1 and Sox9). A final step in the chain of 
evidence consisted of yeast-two hybrid, over-expression, 
and gene-silenecing studies showing that gankyrin interacts 
with SHP-1 to induce activation of STAT3 and MAP kinases 
and then to induce TNF-α production. In accordance with 
this, a physical interaction between gankyrin and SHP-1 was 
detected in immune cells of the colon tissue of gankyrin-
intact mice treated with AOM and DSS. Collectively, these 
data strongly suggest that gankyrin-expressing myeloid 
cells produce pro-inflammatory cytokines through its 
interaction with SHP-1 followed by STAT3 activation and 
then promote CAC through induction of stem cell markers. 
Thus, we propose gankyrin as a tumor promoter that plays 
a role in the interface between immune cells and epithelial 
cells. It should be noted, however, that confirmation of this 
notion awaits future studies addressing the relationship 
between gankyrin expression and colon cancer prognosis 
as well as those addressing the role of gankyrin in immune 
cells by using myeloid, T cell, or B cell-specific gankyrin 
deletion mice.
Taken together, gankyrin, whose expression is 
upregulated by chronic inflammation, increases STAT3 
activity and the production of TNF-α and IL-17 by binding 
to SHP-1 in inflammatory cells, leading to augmented 
inflammation. Such pro-inflammatory cytokine responses 
may enhance MAP kinase activity in the tumor and 
upregulate expression of stem cell markers in the colon. 
These factors would eventually promote CAC (Figure 6). 
Figure 6: Chronic inflammation increases gankyrin expression in the colonic mucosa of patients with IBD. In inflammatory 
cells, gankyrin activates STAT3 by binding to SHP-1, leading to enhanced inflammation. These augmented inflammatory responses would 
activate ERK in tumors and eventually promote colitis-associated cancer.
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Thus, suppression and measurement of gankyrin expression 
is a promising approach for advanced treatment and 
personalized management of IBD patients.
PATIENTS AND METHODS
Human tissue samples
UC and CD were diagnosed as previously described 
[38]. In total, 344 intestinal mucosa specimens were 
obtained by endoscopy from UC patients including 109 
cases of refractory UC, 106 cases of non-refractory active 
UC, 40 cases in remission, as well as 35 CD patients and 
54 normal controls without IBD and gankyrin expression 
was assessed. Among 344 intestinal mucosa specimens, 
111 intestinal samples were obtained between April 2011 
and March 2013 and analyzed for the expression of several 
genes. CAC specimens were obtained from 10 patients 
who had undergone surgery. Refractory IBD was defined 
according to endoscopic criteria and categorized as being 
active for more than 6 months. Active inflammation was 
defined as Mayo endoscopic score ≥2 in UC cases and a 
presence of ulcer in CD cases or presence of symptoms. 
The Mayo score was previously described [39]. The 
clinical study protocol conformed to the ethical guidelines 
of the 1975 Declaration of Helsinki and was approved by 
the relevant institutional review boards.
Generation of mice with tissue-specific deletion 
of the gankyrin gene
Targeted ES clones were isolated from HK3i ES 
cells [40]. Chimeric mice were generated as described [41] 
and crossed with C57BL/6 mice to obtain heterozygous 
Gankyrinflox/wt mice (Accession No. CDB0944K) 
[42]; Gankyrinflox/wt, Mx1-Cre, and Villin-Cre (Jackson 
laboratory) mice were used to create tissue-specific 
conditional gankyrin knockout mice, designated here 
as Mx1-Cre;Gankyrinf/f and Vil-Cre;Gankyrinf/f mice. 
Induction of Mx1-Cre was achieved by 3 intraperitoneal 
injections of 300 μg of poly(I:C) (Sigma-Aldrich, St. 
Louis, MO) every other day to 4–8-week-old mice.
Mouse treatment
Mx1-Cre;Gankyrinf/f mice and Gankyrinf/f mice were 
treated with poly(IC) as described previously [43]. Sex- 
and age-matched poly(IC)-treated Mx1-Cre;Gankyrinf/f 
mice (referred to as Mx1-Cre;Gankyrinf/f mice), poly(IC)-
treated Gankyrinf/f mice, Vil-Cre;Gankyrinf/f mice and 
Gankyrinf/f mice (8–16 weeks old) received 2.5% (w/v) 
dextran sodium sulfate (DSS; molecular weight, 36,000–
50,000 kDa; MP Biomedicals, Solon, OH) in drinking 
water for 7 days. Inflammatory cell infiltration score 
was assessed as described previously [6]. Isolation of 
lamina propria (LP) cells was performed as described 
previously [6]. As the protocol for the murine CAC model 
[6], mice were intraperitoneally (i.p.) injected with 12.5 
mg/kg azoxymethane (AOM; Sigma-Aldrich). After 5 
days, 2.0% DSS was included in the drinking water for 
5 days, followed by 16 days of regular water. This cycle 
was repeated three times. Then, 1.5% DSS was included 
in the drinking water for 4 days, followed by 7 days of 
regular water. Upon sacrifice, the colon was excised from 
the ileocecal junction to the anus, cut open longitudinally, 
and prepared for histological evaluation. Colons were 
assessed macroscopically for polyps under a dissecting 
microscope. All animal procedures were performed 
according to approved protocols and in accordance 
with the recommendations for the proper care and use 
of laboratory animals. The animal study protocol was 
approved by the Medical Ethics Committee of Kindai 
University Faculty of Medicine and Institutional Animal 
Care and Use Committee of RIKEN Kobe.
Cell culture
THP-1 cells, an immortalized line of human 
monocyte, were maintained in RPMI-1640 medium 
(Gibco, Carlsbad, CA) supplemented with 10% fetal 
bovine serum, containing penicillin (100 U/ml) and 
streptomycin (100 mg/ml) and transfection of gankyrin 
siRNA and SHP-1 siRNA (Santa Cruz, Dallas, TX) was 
carried out using X-treme GENE siRNA Transfection 
Reagent (Roche, Basel, Switzerland). Caco2 and U-2 
OS cells were maintained in DMEM medium (Gibco) 
supplemented with 10% fetal bovine serum, containing 
penicillin (100 U/ml) and streptomycin (100 mg/ml) 
and transfected with plasmid using Fugene (Promega, 
Madison, WI) and X-treme GENE HP DNA transfection 
reagent (Roche). Cell viability was assessed using Cell 
Counting Kit-8 (Dojindo, Tokyo, Japan). Jurkat cells 
were transfected with a plasmid containing 3HA-gankyrin 
cDNA.
Biochemical and immunochemical analyses
Real-time qPCR, immunoblotting, 
immunoprecipitation and immunohistochemistry were 
previously described [6, 44]. List of primer sequences 
and FACS protocols are mentioned in Supplementary 
Materials and Methods. The following antibodies were 
used: anti-actin, anti-FLAG, anti-biotin conjugated FLAG 
(Sigma-Aldrich); anti-Bmi1, anti-phospho-STAT3, anti-
STAT3, anti-phospho- extracellular signal-regulated protein 
kinase (ERK), anti-ERK, anti-phospho-c-Jun N-terminal 
kinase (JNK), anti-JNK, anti-phospho-p38, anti-p38 (Cell 
Signaling, Danvers, MA); anti-HA, anti-biotin conjugated 
HA (Roche), anti-SHP-1 (R&D systems, Minneapolis, 
MN) and anti-CD3, anti-CD11b, anti-CD20, anti-CD68, 
anti-CD138 (BD bioscience, San Jose, CA). Generation of 
anti-gankyrin polyclonal antibody was previously described 
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[45]. Immunohistochemistry was performed using 
ImmPRESS™ reagents (Vector Laboratory, Burlingame, 
CA) according to the manufacturer’s recommendations.
Duolink fluorescence method was employed as per 
manufacturer’s recommendations (Sigma Aldrich). Human 
gankyrin antibody and SHP-1 antibody (R&D systems) 
were used to assess gankyrin/SHP-1 interactions under 
confocal laser microscope.
Using the full length of gankyrin as bait, a cDNA 
library from human fetal intestine was screened by the 
yeast two-hybrid method, which was done by Invitrogen 
(Carlsbad, CA). Thirty-seven clones of yeast clones 
transformed with a human intestinal cDNA library were 
identified. Each clone proliferated on media containing 
the histidine inhibitor 3AT and was positive for 
β-galactosidase staining. DNA sequencing of the rescued 
plasmids revealed that two clones encoded SHP-1.
Immunofluorescent TUNEL staining was performed 
to measure apoptosis in paraffin-embedded sections 
using the In Situ Apoptosis Detection Kit as described 
by the manufacturer (Takara, Tokyo, Japan) and previous 
report [6]. Nuclei were stained with 4’, 6diamidino-2-
phenylindole (DAPI) to count the total cells per crypt.
Statistical analysis
Differences were analyzed using Student’s t-test. To 
compare variables of more than 2 conditions, analysis of 
variance (ANOVA) with post-hoc Tukey-Kramer honestly 
significant difference (HSD) multiple comparison was 
applied. The relationship between the expression of several 
genes was analyzed by Spearman’s rank correlation test. P 
values <0.05 were considered significant.
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